Premium
Expression pattern of key micro RNA s in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Author(s) -
Fallah P.,
Amirizadeh N.,
Poopak B.,
Toogeh G.,
Arefian E.,
Kohram F.,
Hosseini Rad S. M. A.,
Kohram M.,
Teimori Naghadeh H.,
Soleimani M.
Publication year - 2015
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.12351
Subject(s) - microrna , myeloid leukemia , cancer research , chromosomal translocation , haematopoiesis , oncogene , biology , downregulation and upregulation , gene silencing , stem cell , k562 cells , leukemia , cancer , medicine , immunology , gene , cell cycle , genetics
Summary Introduction Chronic myeloid leukemia ( CML ) is caused by reciprocal translocation in hematopoietic stem cells ( HSC s). This translocation forms the BCR ‐ ABL 1 oncogene, which alters several signaling pathways that control malignancy. CML has three phases: chronic, accelerated, and blast crisis. The micro RNA s (mi RNA s or miRs) are noncoding RNA s that downregulate their target gene by targeting 3′ UTR of mRNA or through translational inhibition. It has been shown that mi RNA s regulate many biological processes, and dysregulation of these regulatory RNA s is involved in disease development, particularly in cancer. The important role of mi RNA s as therapeutic agents and biomarkers has been demonstrated in CML patients at different phases of the disease. Methods Stem‐loop reverse transcription polymerase chain reaction was used to characterize differentially expressed mi RNA s of leukocytes in the peripheral blood of 50 newly diagnosed CML patients in chronic phase. Results Some onco‐mi RNA s were found to be downregulated (miR‐155 and miR‐106), and some tumor suppressor miRs (miR‐16‐1, miR‐15a, miR‐101, miR‐568) were upregulated. Conclusion These results show that very few mi RNA s alone would be good candidates for CML diagnosis independently of conflicting results, but together could be an additional tool for CML diagnosis. Moreover, mi RNA s might be good candidates for prognosis prediction and CML therapy.